| 代码 | 名称 | 收盘价 | 涨跌幅 | 成交量(手) | 成交额(元) | | | --- | --- | --- | --- | --- | --- | --- | | 300111 | 向日葵 | 7.29 | 11.98% | 167.84万 | | 11.97亿 | | 000766 | 通化金马 | 27.87 | 9.98% | 46.86万 | | 12.97亿 | | 002940 | 昂利康 | 38.66 | 7.87% | 25.79万 | | 9.79亿 | | 300401 | 化园生物 | 17.36 | 5.60% | - 54.32万 | | 2666 | | 920367 | 新赣江 | 23.50 | 5.48% | 5.45万 | | 1.26亿 | | 688176 | 亚虹医药 | 12.60 | 5.09% | 19.90万 | | 2.45亿 | | 301281 | 科源制药 | 30.83 | 5.08% | 4.03万 | | 1.22亿 | | 000908 | *ST景峰 | 8.19 | 5.00% | 3.17万 | | 2599.61万 | ...

Core Viewpoint - The report highlights the growth of industrial enterprises in Jilin Province, indicating a positive trend in the industrial sector with a year-on-year increase in the number of enterprises [1] Group 1: Company Information - Listed companies mentioned include Liyuan Co., Ltd. (002501), ST Jinhong (000669), Changchun Gas (600333), Quanyuan Spring (600189), Tonghua Jinma (000766), Xidian Pharmaceutical (301130), Jilin Carbon Valley (836077), Zhongyan Co., Ltd. (688716), Zhiyuan New Energy (300985), FAW Jiefang (000800), Jilin Expressway (601518), and Jilin Electric Power (000875) [1] Group 2: Industry Statistics - As of January-November 2025, the number of industrial enterprises in Jilin Province reached 3,539, an increase of 142 compared to the same period last year, representing a growth rate of 4.18% [1] - The proportion of Jilin's industrial enterprises accounts for 0.67% of the national total [1] Group 3: Research and Consulting - Zhiyan Consulting is identified as a leading industry consulting firm in China, specializing in deep industry research reports, business plans, feasibility studies, and customized services [1] - The firm emphasizes its commitment to providing comprehensive industry solutions to empower investment decisions [1]

Core Viewpoint - Tonghua Golden Horse has developed a Class 1 chemical new drug, Amber Dihydroaminoacridine Tablets, primarily for the treatment of mild to moderate Alzheimer's disease. The drug has completed comprehensive review work and is currently in the final review stage, with all progress reported as normal. Major information regarding the new drug will be disclosed through designated media outlets [2]. Company Summary - The new drug, Amber Dihydroaminoacridine Tablets, is aimed at treating mild to moderate Alzheimer's disease [2]. - The company has completed the comprehensive review process for the new drug and is now in the final review phase [2]. - All progress related to the new drug is reported to be on track, indicating a positive development timeline [2].

Group 1 - The chemical pharmaceutical sector increased by 0.24% on January 8, with Bibete leading the gains [1] - The Shanghai Composite Index closed at 4082.98, down 0.07%, while the Shenzhen Component Index closed at 13959.48, down 0.51% [1] - Notable gainers in the chemical pharmaceutical sector included Bibete, which rose by 20.00% to a closing price of 49.68, and Qijingt, which increased by 10.00% to 28.27 [1] Group 2 - The chemical pharmaceutical sector experienced a net outflow of 191 million yuan from institutional investors, while retail investors saw a net inflow of approximately 84.42 million yuan [2] - The trading volume for Bibete was 140,500 shares, with a transaction value of 682 million yuan, indicating strong market interest [1] - The sector's overall trading activity showed a mix of inflows and outflows, with specific stocks like Hainan Haiyao and Xinyu Pharmaceutical seeing significant institutional interest [3]

Core Viewpoint - The company Tonghua Jinma (000766.SZ) has provided an update on its new drug development, specifically the chemical Class 1 new drug, Amber Dihydroaminoacridine Tablets, which is primarily aimed at treating mild to moderate Alzheimer's disease. The drug has completed comprehensive review work and is currently in the final review stage, with all progress being normal. The company will disclose significant information regarding the new drug through designated information disclosure media, urging investors to pay attention to company announcements [2]. Group 1 - The new drug Amber Dihydroaminoacridine Tablets is intended for the treatment of mild to moderate Alzheimer's disease [2]. - The drug has completed comprehensive review work and is now in the final review stage [2]. - The company assures that all progress related to the new drug is normal [2].

Core Viewpoint - Tonghua Jinma's stock price has shown volatility, with a recent increase of 2.14% but a year-to-date decline of 1.16%, indicating potential challenges in the market [1]. Financial Performance - For the period from January to September 2025, Tonghua Jinma reported revenue of 892 million yuan, a year-on-year decrease of 7.88%, while net profit attributable to shareholders was 24.96 million yuan, reflecting a growth of 4.35% [2]. - Cumulative cash dividends since the A-share listing amount to 210 million yuan, with no dividends paid in the last three years [3]. Shareholder Structure - As of September 30, 2025, the number of shareholders decreased by 3.20% to 38,200, while the average number of circulating shares per person increased by 3.31% to 25,266 shares [2]. - The top ten circulating shareholders include notable entities such as Innovation Drug and Southern CSI 1000 ETF, with changes in their holdings indicating shifts in investor sentiment [3].

登录新浪财经APP 搜索【信披】查看更多考评等级 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有虚假记载、误导性陈述或重大遗 漏。 一、董事会会议召开情况 1.通化金马药业集团股份有限公司第十一届董事会2025年第十次临时会议通知于2025年12月30日以微信 和电子邮件形式送达全体董事。 2.2025年12月31日上午9时30分以现场和通讯方式召开。 3.会议应到董事9人，实到董事9人。 4.会议由董事长张玉富先生主持，部分高管人员列席了本次会议。 5.本次董事会会议的召开符合有关法律、行政法规、部门规章、规范性文件和公司章程的规定。 二、董事会会议审议情况 审议并通过《关于公司以自有资产抵押向银行申请贷款的议案》 公司与中国建设银行股份有限公司通化分行不存在关联关系，本次申请贷款不构成关联交易，也不构成 《上市公司重大资产重组管理办法》规定的重大资产重组，根据《深圳证券交易所股票上市规则》和 《公司章程》等相关规定，本事项经公司董事会审议后，无须提交公司股东会审议。 表决结果：同意9票，反对0票，弃权0票。 三、备查文件 经与会董事签字并加盖董事会印章的董事会决议。 鉴于2025年公司向中 ...

本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有虚假记 载、误导性陈述或重大遗漏。 一、董事会会议召开情况 4.会议由董事长张玉富先生主持，部分高管人员列席了本次会议。 1.通化金马药业集团股份有限公司第十一届董事会2025年第十次临时会议通知 于2025年12月30日以微信和电子邮件形式送达全体董事。 2.2025 年 12 月 31 日上午 9 时 30 分以现场和通讯方式召开。 3.会议应到董事9人，实到董事9人。 证券代码：000766 证券简称：通化金马 公告编号：2025-46 通化金马药业集团股份有限公司 第十一届董事会 2025 年第十次临时会议决议公告 5.本次董事会会议的召开符合有关法律、行政法规、部门规章、规范性文件和 公司章程的规定。 二、董事会会议审议情况 审议并通过《关于公司以自有资产抵押向银行申请贷款的议案》 鉴于 2025 年公司向中国建设银行股份有限公司通化分行申请的贷款即将到期， 为满足公司生产经营和发展的需要，公司拟再次向中国建设银行股份有限公司通化 分行申请最高额不超过 12,000 万元的融资贷款，在该额度期限内可循环滚动使用。 | 抵押人 | 抵押物名 ...

Core Viewpoint - The company, Tonghua Golden Horse, has announced a resolution from its 11th Board of Directors meeting to apply for a loan from the bank using its own assets as collateral, indicating a strategic move to secure financing for operational needs [1] Group 1: Loan Application Details - The company plans to apply for a financing loan not exceeding 120 million yuan, which is intended to be used in a revolving manner within the specified period [1] - The loan application is in response to an upcoming maturity of a loan previously applied to the Bank of China, Tonghua Branch, in 2025 [1] Group 2: Collateral Information - The financing will be secured by part of the company's own land and properties, with a total book value of 194.9281 million yuan as of September 30, 2025 [1] - The collateral represents 4.24% of the company's most recent audited total assets, indicating a relatively low leverage ratio [1] Group 3: Voting Outcome - The resolution to approve the loan application received unanimous support, with 9 votes in favor, 0 against, and 0 abstentions [1]

Core Viewpoint - Tonghua Jinma's stock price has shown significant growth this year, with an increase of 82.23% year-to-date, indicating strong market performance and investor interest [1][2]. Financial Performance - For the period from January to September 2025, Tonghua Jinma reported operating revenue of 892 million yuan, a year-on-year decrease of 7.88%, while net profit attributable to shareholders was 24.96 million yuan, reflecting a year-on-year increase of 4.35% [2]. - The company has cumulatively distributed 210 million yuan in dividends since its A-share listing, with no dividends paid in the last three years [3]. Stock Market Activity - As of December 22, the stock price was 28.61 yuan per share, with a market capitalization of 27.651 billion yuan. The stock experienced a trading volume of 334 million yuan and a turnover rate of 1.23% [1]. - The stock has appeared on the "龙虎榜" (a list of stocks with significant trading activity) twice this year, with the most recent appearance on September 11, where it recorded a net buy of 142 million yuan [1]. Shareholder Structure - As of September 30, 2025, the number of shareholders was 38,200, a decrease of 3.20% from the previous period, with an average of 25,266 shares held per shareholder, an increase of 3.31% [2]. - The top ten circulating shareholders include notable entities such as Innovation Drug and Southern CSI 1000 ETF, with varying changes in their holdings compared to the previous period [3].